Acute myocardial infarction following erlotinib treatment for NSCLC: A case report

Ding,Shanshan; Long,Fei; Jiang,Shujuan

doi:10.3892/ol.2016.4508

June-2016 Volume 11 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June-2016 Volume 11 Issue 6

Full Size Image

Case Report

Acute myocardial infarction following erlotinib treatment for NSCLC: A case report

Authors:
- Shanshan Ding
- Fei Long
- Shujuan Jiang
View Affiliations / Copyright

Affiliations: Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Pages: 4240-4244
|
Published online on: April 28, 2016

https://doi.org/10.3892/ol.2016.4508
Expand metrics +

Abstract

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is an oral targeted anticancer drug that is used to treat non‑small cell lung cancer (NSCLC). Previous studies have confirmed that erlotinib is safe and is well-tolerated by patients. The most common adverse reactions observed following erlotinib treatment include a rash and mild diarrhea. In the current study, the first case of acute myocardial infarction following one month of treatment with erlotinib in a 63‑year‑old male NSCLC patient is presented. The present study highlights the importance of clinicians remaining cautious following erlotinib administration. In elderly NSCLC patients and those with a history of coronary heart disease, cardiac function must be carefully monitored following erlotinib treatment so that serious adverse reactions, such as myocardial infarction, may be identified early and treated quickly.

View Figures

View References

1.	Gaga M, Powell CA, Schraufnagel DE, Schönfeld N, Rabe K, Hill NS and Sculier JP: ATS/ERS Task Force on the Role of the Pulmonologist in the Management of Lung Cancer: An official American Thoracic Society/European Respiratory Society statement: The role of the pulmonologist in the diagnosis and management of lung cancer. Am J Respir Crit Care Med. 188:503–507. 2013. View Article : Google Scholar : PubMed/NCBI
2.	Zhi X, Wu Y, Ma S, Wang T, Wang C, Wang J, Shi Y, Lu Y, Liu L, Liu D, et al: Chinese guidelines on the diagnosis and treatment of primary lung cancer (2011 version). Zhongguo Fei Ai Za Zhi. 15:677–688. 2012.(In Chinese). PubMed/NCBI
3.	Li HR and Sun F: Erlotinib serious adverse reactions and preventive measures. Chin J Pharmacoepidemiol. 19:232–233. 2010.(In Chinese).
4.	Orphanos GS, Ioannidis GN and Ardavanis AG: Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 48:964–970. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, et al: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 370:2011–2019. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Reck M, Mok T, Wolf J, Heigener D and Wu YL: Reviewing the safety of erlotinib in non-small cell lung cancer. Expert Opin Drug Saf. 10:147–157. 2011. View Article : Google Scholar : PubMed/NCBI
7.	Merimsky O, Cheng CK, Au JS, von Pawel J and Reck M: Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer. Oncol Rep. 28:721–727. 2012.PubMed/NCBI
8.	Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M and Heigener D: Erlotinib in advanced non-small cell lung cancer: Efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol. 5:1616–1622. 2010. View Article : Google Scholar : PubMed/NCBI
9.	Wu YL, Kim JH, Park K, Zaatar A, Klingelschmitt G and Ng C: Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study. Lung cancer. 77:339–345. 2012. View Article : Google Scholar : PubMed/NCBI
10.	Doherty KR, Wappel RL, Talbert DR, Trusk PB, Moran DM, Kramer JW, Brown AM, Shell SA and Bacus S: Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 272:245–255. 2013. View Article : Google Scholar : PubMed/NCBI
11.	Wu X, Gao G, Ren S and Zhou C: Four cases of interstitial lung disease induced by erlotinib and a review of the literatures. Zhongguo Fei Ai Za Zhi. 15:494–498. 2012.(In Chinese). PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Acute myocardial infarction following erlotinib treatment for NSCLC: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles